Sentence examples for modest binding to from inspiring English sources

Binding activity of HB-002.1 HB-002.1B and PIGF was also investogated by ELISA, showing a modest binding to VEGF-B but low binding to PIGF.

Likewise, mouse Siglec-E and F bound strongly to TLR4, with Siglec-3 and H showing modest binding to TLR4, and no binding to TLR4 and Siglec-1, 2 and G. Comparisons between Figure 1A,E, and between Figure 1C,G, show that, with the modest exception of Siglec-7, recombinant TLR4 recapitulated the specificity of endogenous TLR4.

However, all three ligand also showed modest binding affinity to the AD homogenates and lack selectivity for α-synuclein.

A target-based high-throughput screen against T. cruzi CYP51 by the research group at Vanderbilt identified the amide form of indomethacin (COX-2 inhibitor), which displayed modest binding affinity to CYP51 and antiparasitic potency against T. cruzi in cell-based assay.

In vivo, the interactions used by macrophages to survey RBCs for signs of aging 14, possibly enhanced by ex vivo alterations to the RBCs, might augment the modest Ab binding to FcγRIIa and FcγRIIb.

Because of this extraordinarily high degree of variation in the ligand binding site, as well as relatively modest binding affinity (Kd of tens-to-hundreds µM), it is extremely difficult to predict binding partners for the large BRD family with knowledge of only three available structures of BRD and acetyl-lysine-peptide complexes [6].

A first-coordination-sphere match, in which the binding ligands are three neutral His residues, is enough to achieve a modest binding affinity (Kd on the order of ∼10 6 M) and substantial catalytic activity, and only small variations are observed depending on the surrounding structure.

Upon exogenous expression of A12FL or A12Mut, a modest increase in binding to α3 was observed while binding to the αv antibody was greatly increased as was binding to αvβ3 (Figure 6B).

Pep1 shows the highest level of binding to immobilized Bcl-xL (∼80%), while Pep2 shows modest binding (∼1%).

This binding could be competitively inhibited by excess unlabeled HepcARE (lane 5); mutant HepcARE could not bind to the nuclear component and compared with control we found only modest binding in nuclear extracts from cells treated with FeSO4 (Fig. 6 A, lanes 2and 9 respectively).

The main strengths of the concept are that a small set of polypeptides can be used to develop binder molecules for any protein by conjugation to small molecules or peptides with only modest binding capacities, and that the binder molecules target the proteins that the small molecules recognise but with much improved affinity and selectivity.